Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced Biliary Tract Carcinoma
NCT03704480Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- Nov 2018
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in biliary tract carcinoma (BTC), sponsored by GERCOR. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT03704480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704480.